SCHEMBL4057433

SCHEMBL4057433

FC(F)(F)c1cc(-c2nc3ccc(Br)cc3o2)cc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.43
S1PR3 Q99500 2/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
ESR1 P03372 4/20 0.42
ESR2 Q92731 4/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HDAC6 Q9UBN7 3/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057037 0.92 HDAC6 (0.41) S1PR1S1PR3NPC1RAB9AESR1
SCHEMBL14243239 0.88 HDAC6 (0.53) NPC1RAB9AESR1ESR2KDM4E
SCHEMBL4058097 0.87 UTRN (0.48) NPC1RAB9AKDM4EMEN1MAPT
SCHEMBL30791601 0.87 SMN1; SMN2 (0.47) NPC1RAB9AKDM4EMEN1MAPT
SCHEMBL4057301 0.80 HDAC6 (0.47) NPC1RAB9AESR1ESR2KDM4E
SCHEMBL23387567 0.79 NPC1 (0.59) NPC1RAB9AESR1ESR2KDM4E
SCHEMBL2587833 0.77 HDAC6 (0.60) NPC1RAB9AESR1ESR2KDM4E
SCHEMBL25338755 0.77 HPGD (0.56) NPC1RAB9AKDM4EMEN1MAPT
SCHEMBL14243226 0.77 HDAC6 (0.63) NPC1RAB9AESR1ESR2KDM4E
SCHEMBL2139699 0.76 SMN1; SMN2 (0.57) NPC1RAB9AESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B S1PR1 2529/4885S1PR3 2516/4885NPC1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.